Not an actual patient.

For 40 years,
healthcare providers like you have used CLODERM® Cream to provide efficacy with tolerability when treating corticosteroid-responsive dermatoses.1,2

For 40 years,
healthcare providers like you have used CLODERM® Cream to provide efficacy with tolerability when treating corticosteroid-responsive dermatoses.1,2

Not an actual patient.

Results You Can Rely On*

Proven efficacy in treating corticosteroid-responsive dermatoses2

efficacy Image

Not an actual patient.

Day 4: 65%

(65% versus 31% for placebo; P<.001)2

In a clinical study, statistically significant improvement of symptoms was demonstrated at day 4

Day 7: 62%

(62% versus 35% for placebo; P<.01)2

Efficacy in treatment was maintained at day 7

Day 14: 71%

(71% versus 28% for placebo; P<.001)2

At day 14, significant efficacy was noted

Overall: 72%

(72% versus 27% for placebo; P<.001)2

Overall efficacy at completion of treatment

Results of a double-blind, simultaneous, symmetric, paired-comparison clinical trial (left side versus right side) involving patients (n=100) with eczema/atopic dermatitis evaluating the efficacy and safety of clocortolone pivalate 0.1% versus a placebo cream base.2
*Objective criteria included decrease of erythema, edema, transudation and, if present, vesicles or bullae, papules, plaques, scaling, crusting, fissures, and lichenification.

Clocortolone Pivalate Structure

A Design That’s

One-of-a-Kind

CLODERM is formulated to enhance lipid solubility5

Structural modifications (shown in teal) are associated with:

  • Increased anti-inflammatory activity3,6
  • Reduced mineralocorticoid activity and allergenicity6
  • Enhanced percutaneous absorption3,6

The Established
Safety Profile You Know

A well-tolerated mid-potent corticosteroid

  • No age restrictions on use. Children being treated in the diaper area should not wear tight-fitting diapers or plastic pants1
  • Applicable on most areas of the body.
    Contact with eyes and mouth should be avoided1
  • In allergy group C, a group that exhibits the
    lowest potential risk for allergic contact dermatitis induced by a topically applied corticosteroid7
  • No systemic, cumulative, or delayed
    adverse events     related to study drug were observed during treatment up to 7 months8

The Established
Safety Profile You Know

A well-tolerated mid-potent corticosteroid

  • No age restrictions on use. Children being treated in the diaper area should not wear tight-fitting diapers or plastic pants1
  • Applicable on most areas of the body.
    Contact with eyes and mouth should be avoided1
  • In allergy group C, a group that exhibits the
    lowest potential risk for allergic contact dermatitis induced by a topically applied corticosteroid7
  • No systemic, cumulative, or delayed
    adverse events     related to study drug were observed during treatment up to 7 months8

Not an actual patient.

Does Jessica Remind You of Any of Your Patients?

  • 26-year-old, no previous history of corticosteroid-responsive dermatoses
  • Started using a new cleanser; 10 days later she began to develop a rash on her cheeks, neck, and arms
  • Complains about rash stinging and burning, and her skin feeling dry
  • Prescribed hydrocortisone and told to discontinue using her new cleanser
  • Before her next appointment, her rash had not improved

For your patients like Jessica, consider:

  • CLODERM can be safely used on the face9
  • Lanolin-free and does not contain propylene glycol/added fragrance1
  • Has been shown to improve symptoms in as little as 4 days2
  • $0 co-pay for eligible patients†

†Limitations apply. For insured and uninsured eligible patients. See co-pay card for details.


INDICATION AND IMPORTANT SAFETY INFORMATION
CLODERM Cream is indicated for the relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses. The most common adverse events with CLODERM Cream include burning, itching, irritation, dryness, and folliculitis. CLODERM Cream is contraindicated in patients who are hypersensitive to any of the ingredients of this product. As with all topical corticosteroids, systemic absorption can produce reversible HPA-axis suppression.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit http://www.fda.gov/Safety/MedWatch or call 1-800-FDA-1088.

Click here to see Full Prescribing Information.

References: 1. Cloderm [package insert]. Charleston, SC: EPI Health, LLC; 2018. 2. Rosenthal AL. Clocortolone pivalate: a paired comparison clinical trial of a new topical steroid in eczema/atopic dermatitis. Cutis. 1980;25(1):96-98. 3. Del Rosso JQ, Kircik L. A comprehensive review of clocortolone pivalate 0.1% cream: structural development, formulation characteristics, and studies supporting treatment of corticosteroid-responsive dermatoses. J Clin Aesthet Dermatol. 2012;5(7):20-24. 4. Kircik LH. A study to assess the occlusivity and moisturization potential of three topical corticosteroid products using the skin trauma after razor shaving (STARS) bioassay. J Drugs Dermatol. 2014;13(5):582-585. 5. Bikowski J, Pillai R, Shroot B. The position not the presence of the halogen in corticosteroids influences potency and side effects. J Drugs Dermatol. 2006;5(2):125-130. 6. Katz M, Gans EH. Topical corticosteroids, structure-activity and the glucocorticoid receptor: discovery and development—a process of ‘‘planned serendipity.’’ J Pharm Sci. 2008; 97 (8): 2936-2947.    7. Jacob SE, Steele T. Corticosteroid classes: A quick reference guide including patch test substances and cross-reactivity. J Am Acad Dermatol. 2006;54(4):723-727. 8. Nierman MM. Safety and efficacy of clocortolone pivalate 0.1 percent cream in the treatment of atopic dermatitis, contact dermatitis, and seborrheic dermatitis. Cutis. 1981;27(6):670-671. 9. Kircik LH, Del Rosso JQ. The treatment of inflammatory facial dermatoses with topical corticosteroids: focus on clocortolone pivalate 0.1% cream. J Drugs Dermatol. 2012;11(10):1194-1198.